Drug intelligence / Profile preview

TA-A003

Development stage: Preclinical
Lead developer: TALLC Corp.
Modality: Small Molecules

Overview

**TA-A003** is a small molecule drug developed by TALLC Corporation (also referred to as Tallc corporation or TALLC Corp., Inc.) that acts as a **cyclooxygenase 2 (COX-2) inhibitor** and also inhibits the endocannabinoid system (potentially as an endocannabinoid augmenting enzyme inhibitor). It is being developed primarily for **postoperative pain**, with its global highest R&D status at the **preclinical** stage.[1][4][7][10]

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on TA-A003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TA-A003.

Explore the full profile